Enhancing Expression of Functional Human Sodium Iodide Symporter and Somatostatin Receptor in Recombinant Oncolytic Vaccinia Virus for In Vivo Imaging of Tumors
暂无分享,去创建一个
R. Glenn Wells | Richard Wassenaar | B. Vanderhyden | R. Wassenaar | J. Bell | K. Garson | T. Falls | R. Arulanandam | F. Le Boeuf | R. Wells | Julia Petryk | John C. Bell | Jiahu Wang | Rozanne Arulanandam | Theresa Falls | Julia Petryk | Judith Paget | Kenneth Garson | Catia Cemeus | Barbara C. Vanderhyden | Fabrice Le Boeuf | J. Paget | Jiahu Wang | Catia Céméus
[1] G. McFadden,et al. Editorial overview: Oncolytic viruses--replicating virus therapeutics for the treatment of cancer. , 2015, Current Opinion in Virology.
[2] B. Moss,et al. Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[3] B. Vanderhyden,et al. Technical challenges and limitations of current mouse models of ovarian cancer , 2012, Journal of Ovarian Research.
[4] J. Bell. Interfering with tumor pathways that augment viral oncolysis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[5] J. Schlom,et al. Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L). , 1999, Human gene therapy.
[6] R. Ortíz-López,et al. Oncolytic virotherapy. , 2008, Annals of hepatology.
[7] H. Atkins,et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. , 2003, Cancer cell.
[8] J. Bell,et al. Oncolytic viruses: smart therapeutics for smart cancers. , 2012, Future oncology.
[9] J. Barrett,et al. Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[10] J. Darcourt,et al. Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers. , 2008, European journal of endocrinology.
[11] T. Pourcher,et al. Characterisation of the purified human sodium/iodide symporter reveals that the protein is mainly present in a dimeric form and permits the detailed study of a native C-terminal fragment. , 2011, Biochimica et biophysica acta.
[12] Yong Zhang,et al. The evolution of somatostatin in vertebrates. , 2010, Gene.
[13] N. Habib,et al. Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Chemotherapy Induces Potent Immune Responses , 2007, Clinical Cancer Research.
[14] L. Eisenlohr,et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma , 1999, Cancer Gene Therapy.
[15] H. Atkins,et al. Synergistic interaction between oncolytic viruses augments tumor killing. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[16] J. Schlom,et al. Induction of anti-tumor immunity elicited by tumor cells expressing a murine LFA-3 analog via a recombinant vaccinia virus. , 1999, Human gene therapy.
[17] A. De la Vieja,et al. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. , 2000, Physiological reviews.
[18] R. Baldelli,et al. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives , 2010, Journal of experimental & clinical cancer research : CR.
[19] P. Erbs,et al. Modified vaccinia virus Ankara as a vector for suicide gene therapy , 2008, Cancer Gene Therapy.
[20] M. Goris,et al. The Na+/I− Symporter Mediates Iodide Uptake in Breast Cancer Metastases and Can Be Selectively Down-Regulated in the Thyroid , 2004, Clinical Cancer Research.
[21] A. Grimberg. Somatostatin and cancer: Applying endocrinology to oncology , 2004, Cancer biology & therapy.
[22] E. Paoletti,et al. Immunisation with canarypox virus expressing rabies glycoprotein , 1992, The Lancet.
[23] A. Oberg,et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. , 2015, Cancer research.
[24] S. Libutti,et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. , 2001, Cancer research.
[25] J. Goellner,et al. Development of monoclonal antibodies against the human sodium iodide symporter: immunohistochemical characterization of this protein in thyroid cells. , 1999, The Journal of clinical endocrinology and metabolism.
[26] P. Kantoff,et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S. Filetti,et al. Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer , 2014, BMC Cancer.
[28] B. Moss,et al. Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen , 1983, Nature.
[29] P. Santisteban,et al. A perspective view of sodium iodide symporter research and its clinical implications. , 2006, European journal of endocrinology.
[30] E. Konishi,et al. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. , 2000, Vaccine.
[31] J. Bell,et al. A Selectable and Excisable Marker System for the Rapid Creation of Recombinant Poxviruses , 2011, PloS one.
[32] B. O'Malley,et al. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[33] J. Diallo,et al. The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[34] K. Marsh,et al. Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya , 2007, PloS one.
[35] Donna L. Montgomery,et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine , 1996, Nature Medicine.
[36] J. Sakamoto,et al. Effect of thyroid statuses on sodium/iodide symporter (NIS) gene expression in the extrathyroidal tissues in mice , 2010, Thyroid research.